MedTrace Logo

Multi-Center Study of New Medications to Treat Vaginal Infections

NCT02308007 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 475

Last updated 2020-08-04

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the safety and efficacy of terconazole/metronidazole gel in the treatment of vaginal infections

Conditions

  • Vaginal Infection

Interventions

DRUG

Terconazole

DRUG

Metronidazole

DRUG

Terconazole/metronidazole

Sponsors & Collaborators

  • Curatek Pharmaceuticals, LLC

    lead INDUSTRY

Principal Investigators

  • Robert J Borgman, Ph.D. · Curatek Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-06-30
Primary Completion
2018-06-30
Completion
2018-06-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02308007 on ClinicalTrials.gov